Technology Assessment Reports (TARs)
Technology Assessment Reports are detailed analyses of new medicines or medical devices. They are used to determine how cost-effective a product is.
We don't publish most of our Technology Assessment Reports (TARs) because of commercial sensitivity. We do release some reports with the commercial information removed.
TARs inform our prioritisation process.
Published Pharmac Technology Assessment Reports
Daratumumab
Abiraterone acetate
Trikafta (elexacaftor, tezacaftor and ivacaftor) for cystic fibrosis
Download full Trikafta TAR [PDF, 951 KB]
Funded: Trikafta in the Pharmaceutical Schedule(external link)
Freestyle Libre flash glucose monitoring system
Procurement process underway: Update on CGM procurement
Ivacaftor (Kalydeco) for cystic fibrosis with the G551D mutation
TAR 400 Ivacaftor for cystic fibrosis with the G551D mutation [PDF, 1.3 MB]
Supplementary material for TAR 400 [PDF, 447 KB]
Funded: Ivacaftor in the Pharmaceutical Schedule(external link)
SGLT 2 inhibitors (modelled as empagliflozin)
TAR 382 SGLT 2 inhibitors for type 2 diabetes(external link)
Funded: SGLT 2 inhibitors in the Pharmaceutical Schedule(external link)
Ustekinumab (Stelara)
TAR 372 ustkinumab for severe crohn's disease [PDF, 4.8 MB]
Eculizumab (Soliris)
Nusinersen (Spinraza)
TAR 398 Nusinersen for Spinal Muscular Atrophy February 2020 [PDF, 7.4 MB]
Trastuzumab (Herceptin)
- Appendix 1 [PDF, 164 KB]
- Appendix 2 [PDF, 125 KB]
- Appendix 3 [PDF, 61 KB]
- Appendix 4 [PDF, 64 KB]
- Appendix 5 [PDF, 178 KB]
- Appendix 6 [PDF, 511 KB]
TAR 75c Trastuzumab further sensitivity analysis [PDF, 401 KB]
- Appendix 7 to TAR 75c [PDF, 260 KB]
- Appendix 8 to TAR 75c [PDF, 373 KB]
- Appendix 9 to TAR 75c [PDF, 64 KB]
Funded: Trastuzumab in the Pharmaceutical Schedule(external link)
Pembrolizumab (Keytruda)
TAR 271a and 271b Pembrolizumab in advanced melanoma [PDF, 7 MB]
Funded: Pembrolizumab in the Pharmaceutical Schedule(external link)